Geriatric assessment as a predictor of survival among older Indian patients with cancer.

Authors

null

Abhijith Rajaram Rao

Annexe Building, Mumbai, India

Abhijith Rajaram Rao , Anant Ramaswamy , Sharath Kumar Sr., Shreya Gattani , Ratan Dhekale , Jyoti Krishnamurthy , Sarika Mahajan , Anuradha Daptardar , Jayita Deodhar , Manjunath Nookala , Supriya Goud , Sucheta More , Dipti Nakti , Chetan Mudliya , Nandini Sharrel Menon , Vijay Maruti Patil , Vikram Gota , Shripad Dinanath Banavali , Kumar Prabhash , Vanita Noronha

Organizations

Annexe Building, Mumbai, India, Tata Memorial Hospital (HBNI), Mumbai, India, Tata Memorial Hospital, Mumbai, India, Tata Memorial Centre, Mumbai, India, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India, Tata Memorial Center, Mumbai, India

Research Funding

No funding received

Background: ASCO guidelines recommend that geriatric assessment (GA) should be performed in all older adults with cancer. However, GA is labor- and time-intensive, hence the uptake is poor, especially in crowded resource poor-settings. There are no data correlating GA with overall survival (OS) outcomes from the Indian subcontinent. Methods: A prospective observational study in the geriatric oncology clinic of the Tata Memorial Hospital in Mumbai, India. Patients aged 60 years and above, with cancer who underwent a GA were enrolled. The domains assessed included: function (basic and instrumental activities of daily living, timed-up-and-go), nutrition (body mass index, unintentional weight loss, mini-nutritional assessment), comorbidities, cognition, psychological (depression, anxiety), social support, and medication (polypharmacy and potentially inappropriate medications). Patients with > 2 deranged GA domains were considered frail. Results: Between June 2018 and January 2022, 909 patients were enrolled. The median age was 69 (IQR, 60-88) years. Common malignancies included lung (40%), esophagus (21%) and head and neck (11%); 53% had metastatic disease. 80% had > 2 impaired domains in GA patients had vulnerabilities in a median of 3 (IQR, 0-5) domains. Median OS in fit patients based on the GA was 17.5 (95% CI, 13.9-21.0) months vs 12.1 (95% CI, 10.1-14.0) months in frail patients, (HR 0.66; 95% CI, 0.49-0.88, p = 0.005), which remained significant after adjusting for age, sex, and stage (HR, 0.71; 95% CI: 0.53-0.94, p = 0.021). In the multivariate analysis (Table), the domains that were predictive of survival were nutrition (HR: 0.65, 95% CI: 0.47-0.92, p = 0.014), cognition (HR: 0.65; 95% CI: 0.46-0.91, p = 0.012) and fatigue (HR: 0.74, 95% CI: 0.56-0.98, p = 0.038). Conclusions: In older Indian patients with cancer, GA is a powerful prognosticator of survival. In settings where a complete GA is not possible, nutrition, cognition, and fatigue should be the minimum domains assessed. Clinical trial information: CTRI/2020/04/024675.

Multivariate analysis evaluating the association of the geriatric assessment domains with overall survival.

Domains assessed in the GA (n = 909)Overall Survival in monthsMultivariate
Median (95% CI)HR95% CI
Function
Normal
14.2 (12.8-17.4)
0.83
0.63-1.10
Abnormal
9.3 (8.1-12.8)
Falls
Normal
12.9 (10.6-16.6)
1.38
0.89-2.16
Abnormal
14.1 (9.3-16.9)
Nutrition
Normal
17.5 (13.9-24.3)
0.65
0.47-0.92
Abnormal
10.2 (8.7-13.0)
Comorbidities
Normal
12.9 (10.2-17.1)
0.97
0.73-1.29
Abnormal
13.6 (10.7-16.9)
Cognition
Normal
14.5 (12.9-17.3)
0.65
0.46-0.91
Abnormal
8.7 (5.5-12.6)
Psychological
Normal
13.4 (10.3-17.3)
0.99
0.69-1.40
Abnormal
12.1 (6.1-18.0)
Fatigue
Normal
16.8 (12.1-18.0)
0.74
0.56-0.98
Abnormal
9.7 (7.5-14.5)
Medications
Normal
16.6 (10.7-15.7)
1.00
0.74-1.35
Abnormal
12.9 (5.1-16.8)
Social Support
Normal
13.2 (10.7-15.7)
0.89
0.45-1.76
Abnormal
10.9 (5.1-16.8)

HR: hazard ratio; CI: confidence interval

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2022 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Symptoms and Survivorship

Track

Symptom Science and Palliative Care

Sub Track

Geriatric Models of Care

Clinical Trial Registration Number

CTRI/2020/04/024675

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr e24012)

DOI

10.1200/JCO.2022.40.16_suppl.e24012

Abstract #

e24012

Abstract Disclosures

Similar Abstracts

First Author: Takuma Kato

First Author: Chakra Pani Chaulagain

First Author: Kelsey Sokol